21703_LDL Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

In this program, Dr. Lynn Braun and Dr. Michael Miller present lectures and case studies addressing the management of atherosclerotic cardiovascular disease along with best practices and treatment options.

Elevated LDL cholesterol (LDL-C) levels are associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD). Common themes across lipid
guidelines include 1) the aggressive treatment of patients with established ASCVD, primary LDL-C ≥ 190 mg/dL, and diabetes, 2) the importance of a patient-centered
approach and shared decision-making, and 3) the use of follow-up LDL-C as either a target of therapy or to monitor response/adherence. Recent evidence has provided additional support for the concept that for LDL-C, “lower is better”. Despite the well-documented efficacy of statins, many patients are still at risk for
insufficient response to therapy, statin intolerance, and poor treatment adherence. Guidelines have identified vulnerable patient populations who may benefit from
further reductions in LDL-C despite statin therapy. The 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk provides clinicians with an insightful roadmap for treatment. Emerging information with PCSK9 inhibition on major cardiovascular outcomes is important to consider in personalizing treatment of patients with hyperlipidemia.

Login to your Account